UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Operating revenue:
Total operating revenue	$ 6,693	$ 5,203	$ 12,919	$ 10,237
Costs and operating expenses:
Cost of oncology solutions	3,451	2,653	6,533	5,294
Research and development	1,193	1,115	2,282	2,233
Sales and marketing	740	551	1,259	1,235
General and administrative	1,034	954	2,088	2,164
Total costs and operating expenses	6,418	5,273	12,162	10,926
Income (loss) from operations	275	(70)	757	(689)
Other expense:
Other expense	(7)	(13)	(6)	(64)
Total other expense	(7)	(13)	(6)	(64)
Income (loss) before provision for income taxes	268	(83)	751	(753)
Provision for income taxes	1	11	1	15
Net income (loss)	$ 267	$ (94)	$ 750	$ (768)
Net income (loss) per common share outstanding
Net income (loss) per common share outstanding, basic (in dollars per share)	$ 0.02	$ (0.01)	$ 0.07	$ (0.07)
Net income (loss) per common share outstanding, diluted (in dollars per share)	$ 0.02	$ (0.01)	$ 0.06	$ (0.07)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic (in shares)	11,278,312	10,988,321	11,135,358	10,984,703
Weighted average common shares outstanding, diluted (in shares)	14,037,090	10,988,321	13,491,502	10,984,703